Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Nusinersen, marketed as Spinraza, is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. In December 2016, it became the first approved drug used in treating this disorder.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Nusinersen. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
drug sma people spinal 2018 price muscular atrophy first approved used us protein gene clinical type children treatment 2017 2019
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Nusinersen | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Nusinersen | ATC code | M09AX07 (WHO) | 1.00 | infobox |
| Nusinersen | Bioavailability | 100% (intrathecal) | 1.00 | infobox |
| Nusinersen | CAS Number | 1258984-36-9 | 1.00 | infobox |
| Nusinersen | ChemSpider | 34983394 | 1.00 | infobox |
| Nusinersen | DrugBank | DB13161 | 1.00 | infobox |
| Nusinersen | Elimination half-life | 135–177 days (in CSF), 63–87 days (in plasma) | 1.00 | infobox |
| Nusinersen | Formula | C234H323N61Na17O128P17S17 | 1.00 | infobox |
| Nusinersen | KEGG | D10881 | 1.00 | infobox |
| Nusinersen | KEGG | as salt: D10791 | 1.00 | infobox |
| Nusinersen | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Nusinersen | Legal status | CA: ℞-only | 1.00 | infobox |
| Nusinersen | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Nusinersen | Legal status | US: ℞-only | 1.00 | infobox |
| Nusinersen | Legal status | EU: Rx-only | 1.00 | infobox |
| Nusinersen | License data | US DailyMed: Nusinersen | 1.00 | infobox |
| Nusinersen | MedlinePlus | a617010 | 1.00 | infobox |
| Nusinersen | Metabolism | Exonuclease (3'- and 5')-mediated hydrolysis | 1.00 | infobox |
| Nusinersen | Molar mass | 7500.86 g·mol−1 | 1.00 | infobox |
| Nusinersen | Other names | IONIS-SMNRx, ISIS-SMNRx | 1.00 | infobox |
| Nusinersen | Pregnancy category | AU: B1 | 1.00 | infobox |
| Nusinersen | Protein binding | <25% (in CSF), >94% (in plasma) | 1.00 | infobox |
| Nusinersen | PubChem CID | 124037382 | 1.00 | infobox |
| Nusinersen | Routes of administration | Intrathecal | 1.00 | infobox |
| Nusinersen | Trade names | Spinraza | 1.00 | infobox |
| Nusinersen | UNII | 5Z9SP3X666 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.